It’s Time for the FDA To Embrace Digital Technology

  • Artvoice | by: Peter J. Pitts |
  • 04/11/2018 12:00 AM
N/A by N/A is licensed under N/A N/A
The FDA’s drug regulators want to know everything. They require pharmaceutical companies to conduct years of testing to prove that experimental medicines are safe and effective.

This rigorous and mostly prudent approach makes perfect sense when evaluating potent biopharmaceutical products. After all, if the FDA makes a mistake it could endanger thousands of patients.

But such excessive caution isn’t warranted when it comes to a new breed of digital technologies designed to make medicines more effective by making patients more compliant. These technologies — which include ingestible, implantable, portable, and app-based monitoring and diagnostic tools — pose minimal safety risks. Therefore, FDA regulators should subject these products to less scrutiny. That would speed the approval process and enable patients to access these tools sooner.

Patients and their families are excited, rather than fearful or suspicious, about the potential of digital technologies.
Consider Abilify MyCite, a pill with a sensor that digitally tracks whether schizophrenia patients have ingested their medication. This technology could help boost abysmally low rates of medication adherence. Currently, three out of five schizophrenia patients do not take prescriptions as prescribed.

Enabling caregivers and family members to check whether patients have taken their pills could prevent patients’ mental health from deteriorating. The technology could spare patients and families much anguish and prevent costly hospitalizations, thereby lowering overall healthcare spending. Fortunately, the FDA approved the technology in November.

Researchers are incorporating similar sensors into other medications too. The tools could remind dementia patients to take their medicines. Or they could help a parent know if her child actually swallowed her pill or stuck it in her cheek and spit it out later.
 
Article Photo Credit: N/A by N/A is licensed under N/A N/A
Sign Up for Our Email Newsletter

RECENT NEWS

The Spreading Cancer of Counterfeit Drugs
  • CMPI
  • 10/01/2020 12:00 AM

The Spreading Cancer of Counterfeit Drugs

Just as the coronavirus mutates to survive and thrive, so to do the purveyors of counterfeit medicines -- with their high...  Read more

$40 price tag for potential coronavirus vaccine seems to be ‘right on the money,’ says think tank

$40 price tag for potential coronavirus vaccine seems to be ‘right on the money,’ says think tank

If a potential coronavirus vaccine is not affordable, too many people will not get vaccinated, says Peter Pitts, presiden...  Read more

Former FDA Associate Commissioner Says FDA Made Right Move to Authorize Convalescent Plasma

Former FDA Associate Commissioner Says FDA Made Right Move to Authorize Convalescent Plasma

Peter Pitts, President for the Center For Medicine in the Public Interest, explains why he believes the FDA authorized th...  Read more

DRUGWONKS BLOG